Mark Alan Goldberg, SVP, Medical&Regulatory Affairs at SYNAGEVA BIOPHARMA CORP (GEVA), sold 4,416 shares at $54.21 ($240K) on 2013-04-01, disclosed to the SEC on 2013-04-03.
Scheduled sale ($240k) by SVP, Medical&Regulatory Affairs under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $54.21 | 3,797 | $206K | 85.8% |
| 2 | $54.92 | 619 | $34K | 14.2% |
| Total | $54.31 avg | 4,416 | $240K | 100% |
| Filing → |
| BPMC | SELL | 2020-12-22 | $654K | — | Filing → |
| BPMC | SELL | 2020-12-15 | $627K | — | Filing → |
| BPMC | SELL | 2020-12-03 | $600K | — | Filing → |